Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction
- PMID: 7531493
- DOI: 10.1021/bi00006a003
Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction
Abstract
Interactions between gp39 (CD40L, TRAP, T-BAM) on activated T cells and CD40 on antigen-presenting cells play an important role in regulating antibody production by B cells, cytokine production by monocytes, and other immune responses which require T cell "help". Using structure-based sequence alignments, a molecular model of gp39, site-directed mutagenesis, and receptor-ligand binding assays, we have identified CD40 and gp39 surface residues which are important for receptor-ligand binding. Binding studies with CD40 or gp39 proteins containing single and double amino acid substitutions showed that CD40 residues Y82, D84, and N86 are involved in gp39 binding, while gp39 residues K143 and Y145 are important for CD40 binding. Analysis of the location of amino acid substitutions in the naturally occurring gp39 mutants expressed by the X-linked hyper-IgM (X-HIM) patients studied to date indicated the E129/G substitution found in the S128/R-E129/G double mutant affects a solvent-accessible residue which might participate in CD40/gp39 binding. Binding studies with E129/G and E129/A gp39 point mutants showed that this residue does not contribute directly to CD40/gp39 binding but that its substitution with a glycine disrupts the gp39 structure. Comparison of the gp39 and CD40 residues involved in receptor-ligand contacts with those previously identified as playing an important role in TNF-beta/TNFR binding suggests that some of the identified residues from contacts similar to those found in the TNF-beta/TNFR while others are unique to the CD40-gp39 interaction.
Similar articles
-
Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis.Biochemistry. 1995 Aug 8;34(31):9884-92. doi: 10.1021/bi00031a009. Biochemistry. 1995. PMID: 7543281
-
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.Cell. 1993 Jan 29;72(2):291-300. doi: 10.1016/0092-8674(93)90668-g. Cell. 1993. PMID: 7678782
-
In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions.J Exp Med. 1993 Nov 1;178(5):1555-65. doi: 10.1084/jem.178.5.1555. J Exp Med. 1993. PMID: 7693849 Free PMC article.
-
The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.Semin Immunol. 1994 Oct;6(5):337-41. doi: 10.1006/smim.1994.1042. Semin Immunol. 1994. PMID: 7532462 Review.
-
The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.Res Immunol. 1994 Mar-Apr;145(3):210-5; discussion 244-9. Res Immunol. 1994. PMID: 7527577 Review. No abstract available.
Cited by
-
Natural antibodies sustain differentiation and maturation of human dendritic cells.Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14210-5. doi: 10.1073/pnas.0402183101. Epub 2004 Sep 20. Proc Natl Acad Sci U S A. 2004. PMID: 15381781 Free PMC article.
-
A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.Immunology. 2003 Oct;110(2):206-16. doi: 10.1046/j.1365-2567.2003.01717.x. Immunology. 2003. PMID: 14511234 Free PMC article.
-
In silico investigation of Panax ginseng lead compounds against COVID-19 associated platelet activation and thromboembolism.J Ginseng Res. 2023 Mar;47(2):283-290. doi: 10.1016/j.jgr.2022.09.001. Epub 2022 Sep 17. J Ginseng Res. 2023. PMID: 36160270 Free PMC article.
-
Rainbow Trout IgM+ B Cells Preferentially Respond to Thymus-Independent Antigens but Are Activated by CD40L.Front Immunol. 2019 Dec 17;10:2902. doi: 10.3389/fimmu.2019.02902. eCollection 2019. Front Immunol. 2019. PMID: 31921163 Free PMC article.
-
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.Pharmacol Ther. 2021 Mar;219:107709. doi: 10.1016/j.pharmthera.2020.107709. Epub 2020 Oct 20. Pharmacol Ther. 2021. PMID: 33091428 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous